Detail akcie Erasca Rg online

Business Summary: Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Erasca Inc revenues was not reported. Net loss decreased 26% to $95.5M. Lower net loss reflects Research & Development Expense - Balan decrease of 20% to $60.9M (expense), In-process research and development decrease of 58% to $9.5M (expense), Stock-based Compensation in R&D decrease of 16% to $8.7M (expense).